Achillion Pharmaceuticals, Inc. (ACHN) Misses Q4 EPS by 2c; Guides FY12

Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) reported Q4 EPS of ($0.18), $0.02 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $62 thousand versus the consensus estimate of $120 thousand.

Sees FY2012 EPS of $-0.65-$-0.70, versus the consensus of $-0.64.

For earnings history and earnings-related data on Achillion Pharmaceuticals, Inc. (ACHN) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Keefe, Bruyette & Woods Starts Columbia Financial Inc (CLBK) at Outperform
• Deutsche Bank Upgrades PennyMac Mortgage Investment Trust (PMT) to Buy